Christina Binder1, Franz Duca1, Thomas Binder1, René Rettl1, Theresa Marie Dachs1, Benjamin Seirer1, Luciana Camuz Ligios1, Fabian Dusik1, Christophe Capelle1, Hong Qin1, Hermine Agis2, Renate Kain3, Christian Hengstenberg1, Roza Badr Eslam4, Diana Bonderman5. 1. Department of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 2. Department of Internal Medicine I, Department of Oncology, Medical University of Vienna, Vienna, Austria. 3. Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria. 4. Department of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. roza.badreslam@meduniwien.ac.at. 5. Department of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. diana.bonderman@meduniwien.ac.at.
Abstract
BACKGROUND: Pericardial and pleural effusion are common findings in patients with cardiac amyloidosis (CA). It is not known, whether effusions correlate with right ventricular (RV) function in these patients. Furthermore, data on the prognostic significance of pleural and pericardial effusion in CA is scarce. METHODS: Patients with transthyretin (ATTR) and light chain (AL) CA were included in a clinical registry. All patients underwent transthoracic echocardiography at baseline. The presence of pericardial and pleural effusion was determined in every patient. The clinical endpoint was defined as cardiac death or heart failure hospitalization. RESULTS: In total, 143 patients were analysed. Of these, 85 patients were diagnosed with ATTR and 58 patients with AL. Twenty-four patients presented with isolated pericardial effusion and 35 with isolated pleural effusion. In 19 patients, both pericardial and pleural effusion were found and in 65 patients no effusion was present at baseline. The presence of pleural effusion correlated well with poor RV function, measured by global RV free-wall strain (p = 0.007) in patients with AL, but not in ATTR. No such correlation could be found for pericardial effusion in either amyloidosis subtype. Patients with AL presenting with pleural effusion had worse outcomes compared to patients with pericardial effusion alone or no effusion at baseline. In the ATTR group, there was no difference in outcomes according to presence and type of effusion. CONCLUSION: More than 50% of patients with CA presented with pleural and/or pericardial effusions. While pleural effusion was clearly associated with poor RV function in AL, we were not able to detect this association with pericardial effusion.
BACKGROUND: Pericardial and pleural effusion are common findings in patients with cardiac amyloidosis (CA). It is not known, whether effusions correlate with right ventricular (RV) function in these patients. Furthermore, data on the prognostic significance of pleural and pericardial effusion in CA is scarce. METHODS:Patients with transthyretin (ATTR) and light chain (AL) CA were included in a clinical registry. Allpatients underwent transthoracic echocardiography at baseline. The presence of pericardial and pleural effusion was determined in every patient. The clinical endpoint was defined as cardiac death or heart failure hospitalization. RESULTS: In total, 143 patients were analysed. Of these, 85 patients were diagnosed with ATTR and 58 patients with AL. Twenty-four patients presented with isolated pericardial effusion and 35 with isolated pleural effusion. In 19 patients, both pericardial and pleural effusion were found and in 65 patients no effusion was present at baseline. The presence of pleural effusion correlated well with poor RV function, measured by global RV free-wall strain (p = 0.007) in patients with AL, but not in ATTR. No such correlation could be found for pericardial effusion in either amyloidosis subtype. Patients with AL presenting with pleural effusion had worse outcomes compared to patients with pericardial effusion alone or no effusion at baseline. In the ATTR group, there was no difference in outcomes according to presence and type of effusion. CONCLUSION: More than 50% of patients with CA presented with pleural and/or pericardial effusions. While pleural effusion was clearly associated with poor RV function in AL, we were not able to detect this association with pericardial effusion.
Authors: F Aus dem Siepen; R Bauer; A Voss; S Hein; M Aurich; J Riffel; D Mereles; C Röcken; S J Buss; H A Katus; Arnt V Kristen Journal: Clin Res Cardiol Date: 2017-09-27 Impact factor: 5.460
Authors: Martha Grogan; Christopher G Scott; Robert A Kyle; Steven R Zeldenrust; Morie A Gertz; Grace Lin; Kyle W Klarich; Wayne L Miller; Joseph J Maleszewski; Angela Dispenzieri Journal: J Am Coll Cardiol Date: 2016-09-06 Impact factor: 24.094
Authors: Tushar Kotecha; Ana Martinez-Naharro; Thomas A Treibel; Rohin Francis; Sabrina Nordin; Amna Abdel-Gadir; Daniel S Knight; Giulia Zumbo; Stefania Rosmini; Viviana Maestrini; Heerajnarain Bulluck; Roby D Rakhit; Ashutosh D Wechalekar; Janet Gilbertson; Mary N Sheppard; Peter Kellman; Julian D Gillmore; James C Moon; Philip N Hawkins; Marianna Fontana Journal: J Am Coll Cardiol Date: 2018-06-26 Impact factor: 24.094
Authors: Nilam J Soni; Ricardo Franco; Maria I Velez; Daniel Schnobrich; Ria Dancel; Marcos I Restrepo; Paul H Mayo Journal: J Hosp Med Date: 2015-07-28 Impact factor: 2.960
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Grigorios Chatzantonis; Michael Bietenbeck; Ahmed Elsanhoury; Carsten Tschöpe; Burkert Pieske; Gloria Tauscher; Julia Vietheer; Zornitsa Shomanova; Heiko Mahrholdt; Andreas Rolf; Sebastian Kelle; Ali Yilmaz Journal: Clin Res Cardiol Date: 2020-11-10 Impact factor: 5.460
Authors: F Escher; M Senoner; J Doerler; M M Zaruba; M Messner; C Mussner-Seeber; M Ebert; C Ensinger; A Mair; A Kroiss; H Ulmer; S Schneiderbauer-Porod; C Ebner; G Poelzl Journal: Clin Res Cardiol Date: 2019-05-27 Impact factor: 5.460